In what Astella Pharma calls “a landmark decision for advanced bladder cancer patients,” the Japanese drugmaker gained approval in the UK for its treatment regimen. 10 October 2024
Pfizer released positive top line results from the final prespecified overall survival (OS) analysis of the TALAPRO-2 study of Talzenna (talazoparib), an oral poly ADP-ribose polymerase (PARP) inhibitor, in combination with Xtandi (enzalutamide). 10 October 2024
US healthcare giant Johnson & Johnson’s Tecvayli (teclistamab) has been recommended by the National Institute for Health and Care Excellence (NICE) as a first-line option to treat myeloma in England and Wales. 10 October 2024
Cancer start-up Black Diamond Therapeutics has announced a significant restructuring as part of its plan to focus resources on its lead drug, BDTX-1535. 10 October 2024
The European Medicines Agency (EMA) has accepted for review the Marketing Authorization Applications for AVT03, a proposed biosimilar candidate to the Prolia and Xgeva (denosumab), submitted by Germany’s STADA Arzneimittel. 10 October 2024
China’s Quantum Pharmaceuticals has announced a significant licensing agreement between its biologics-focused subsidiary, Ailux Biologics, and Johnson & Johnson. 10 October 2024
Advances in gene editing, such as the FDA approval of Vertex Pharmaceuticals’ Casgevy (exagamglogene autotemcel) in December 2023 for the treatment of beta thalassemia and sickle cell disease, have fueled significant interest in innovative epigenetic drugs. 10 October 2024
German family-owned pharma major Boehringer Ingelheim and USA-based Circle Pharma (have entered into a research collaboration and license agreement with the shared goal to develop a first-in-class cyclin inhibitor that can halt the growth of cancer cells potentially offering hope to those living with hard-to-treat cancers. 9 October 2024
Bayer has entered into a collaboration with MOMA Therapeutics to develop a small molecule oncology program using the latter’s proprietary KNOMATIC platform. 9 October 2024
Genor Biopharma has announced plans for a significant merger with Edding Group, marking one of the first reverse takeovers involving a Hong Kong-listed biopharma company. 8 October 2024
China-headquartered clinical-stage biotech MediLink Therapeutics has announced a global clinical trial collaboration and supply agreement with US major Amgen. 8 October 2024
Germany’s Eckert & Ziegler, a specialist in radioisotopes for medical, scientific and industrial applications, has announced a global clinical supply agreement with GlyTherix, an Australian targeted radiotherapy firm specializing in developing antibody radiopharmaceuticals for solid tumors. 8 October 2024
US clinical-stage biotech OnKure Therapeutics has announced the completion of its previously announced merger with Reneo Pharmaceuticals. 8 October 2024
Daejeon-based Orum Therapeutics, a specialist in degrader-antibody conjugates (DAC), has filed for an initial public offering (IPO) on South Korea's Kosdaq market. 7 October 2024
Mosaic Therapeutics, a UK-based oncology therapeutics company dedicated to resolving cancer’s complexity to power new combination therapies for patients, has announced the appointment of Barry Davies as chief scientific officer. 7 October 2024
Heron Therapeutics last week announced positive, top-line results from its recently completed Phase III MAGIC study with its Sustol (granisetron, extended-release). 1 June 2015
Pharma giant Merck & Co and USA-based Amgen, a leading independent biotech firm, have announced an expansion to an existing collaboration on Keytruda (pembrolizumab). 1 June 2015
Swiss drug major Novartis has announced data from a Phase III study showing a significant survival benefit in BRAF V600E/K mutation-positive metastatic melanoma when treated with the combination of Tafinlar (dabrafenib) and Mekinist (trametinib) compared to Tafinlar as a monotherapy. 1 June 2015
German family-owned pharma major Boehringer Ingelheim on Sunday announced overall survival (OS) results from the LUX-Lung 8 trial (NCT01523587) that directly compared the efficacy and safety of two EGFR-directed treatments, afatinib and erlotinib. 1 June 2015
Bristol-Myers Squibb on Friday announced that Opdivo (nivolumab) is the first PD-1 inhibitor to demonstrate superior overall survival versus standard of care (docetaxel) in an open-label, randomized Phase III study (CheckMate -057). 30 May 2015
Swiss pharma giant Roche announced new data at the American Society of Clinical Oncology (ASCO) annual meeting on Saturday on its cobimetinib in melanoma, as well as on MPDL3280A in lung cancer. 30 May 2015
Results from four pivotal clinical trials show that new targeted therapies could vastly improve treatment for people with chronic-lymphocytic leukemia (CLL), myelofibrosis, indolent non-Hodgkin lymphoma (NHL), and multiple myeloma. 30 May 2015
Eli Lilly and AstraZeneca have entered into a clinical trial collaboration to evaluate the safety and preliminary efficacy of AstraZeneca's investigational anti-PD-L1 immune checkpoint inhibitor, MEDI4736, in combination with Cyramza (ramucirumab). 29 May 2015
UK-based oncology specialist Scancell is aiming to break ahead of the cancer immunotherapy pack. Richard Goodfellow, joint chief executive of the company, discussed his optimism around its lead product, SCIB1. 29 May 2015
Bayer and its development partner Janssen Pharmaceuticals have initiated the CALLISTO Clinical Research Program to explore the potential benefits of the oral Factor Xa inhibitor Xarelto (rivaroxaban) for the prevention and treatment of pulmonary embolism and deep vein thrombosis in patients with various types of cancer. 29 May 2015
US biotech firms bluebird bio and Five Prime Therapeutics have entered into an exclusive license agreement to research, develop and commercialize chimeric antigen receptor (CAR) T cell therapies. 28 May 2015
UK specialty pharmaceutical and services company Clinigen has started a global access program in Europe for Clovis Oncology’s rociletinib, being developed to treat advanced non-small cell lung cancer. 28 May 2015
The European Commission has endorsed the Committee for Medicinal Products for Human Use’s (CHMP) Opinion recommending the approval of Aloxi (palonosetron HCl) from privately-held Swiss cancer specialist Helsinn Group. 27 May 2015
A genetically engineered herpes virus can halt the progression of skin cancer by killing cancer cells and sparking the immune system into action against tumors, a landmark clinical trial has shown. 27 May 2015